Talk recorded by CureTalks on February 14, 2019 at 11 am EST

Each year, roughly 5,000 people of all ages in the United States are diagnosed with Castleman disease, a rare disorder that activates the body's immune system, releasing excess inflammatory proteins that can shut down the liver, kidneys and bone marrow.

David Fajgenbaum, MD, MBA, MSc, associate director of patient impact at the Penn Orphan Disease Center, was diagnosed with the disease nine years ago and founded the Castleman Disease Program at Penn. Dr. Fajgenbaum discusses the current understanding of the disease, symptoms and treatment options, along with new trials and research that may benefit patients.

Share This Page: